PDF(Pubmed)
Abstract：
UNASSIGNED: The increasing antibiotic resistance is the main issue causing Helicobacter pylori (H. pylori) eradication failure. As a nutritional supplement, Egg Yolk Antibody (Ig Y) provides a new approach for H. pylori infection rescue therapy.
UNASSIGNED: In this randomized, controlled study, 100 H. pylori-positive patients with previous H. pylori eradication treatment were included. All individuals received standard bismuth-containing quadruple therapy twice daily (5 mg ilaprazole, 100 mg doxycycline, 500 mg clarithromycin or 1 g amoxicillin or 100 mg furazolidone, and 220 mg colloidal bismuth tartrate) for 14 days and were randomized to receive either twice daily 7 g Ig Y-H. pylori treatment (study group) or not (control group). 4 weeks after the end of treatment, urea breath tests were used to assess the H. pylori eradication rate. All participants scored by the Global Overall Symptom scale (GOS) and recorded adverse events during the trial.
UNASSIGNED: The H. pylori eradication rates were 84.0% (95% CI 73.5-94.5%) vs. 80.0% (95% CI 68.5-91.5%) in the study and control groups at intention-to-treat (ITT) analysis and 85.7% (95% CI 75.6-95.9%) vs. 80.0% (95% CI 68.5-91.5%) at per-protocol (PP) analysis, respectively. The number of over 80% symptom relief after treatment in the two groups was 27 (60%) and 12 (29.2%) (p < 0.05), and the incidences of adverse events were 4 (8%) and 6 (12%), respectively.
UNASSIGNED: Both groups achieved satisfactory eradication efficiency in H. pylori rescue therapy and Ig Y-H. pylori effectively alleviates the symptoms with good compliance and fewer adverse effects.
UNASSIGNED: In this randomized, controlled study, 100 H. pylori-positive patients with previous H. pylori eradication treatment were included. All individuals received standard bismuth-containing quadruple therapy twice daily (5 mg ilaprazole, 100 mg doxycycline, 500 mg clarithromycin or 1 g amoxicillin or 100 mg furazolidone, and 220 mg colloidal bismuth tartrate) for 14 days and were randomized to receive either twice daily 7 g Ig Y-H. pylori treatment (study group) or not (control group). 4 weeks after the end of treatment, urea breath tests were used to assess the H. pylori eradication rate. All participants scored by the Global Overall Symptom scale (GOS) and recorded adverse events during the trial.
UNASSIGNED: The H. pylori eradication rates were 84.0% (95% CI 73.5-94.5%) vs. 80.0% (95% CI 68.5-91.5%) in the study and control groups at intention-to-treat (ITT) analysis and 85.7% (95% CI 75.6-95.9%) vs. 80.0% (95% CI 68.5-91.5%) at per-protocol (PP) analysis, respectively. The number of over 80% symptom relief after treatment in the two groups was 27 (60%) and 12 (29.2%) (p < 0.05), and the incidences of adverse events were 4 (8%) and 6 (12%), respectively.
UNASSIGNED: Both groups achieved satisfactory eradication efficiency in H. pylori rescue therapy and Ig Y-H. pylori effectively alleviates the symptoms with good compliance and fewer adverse effects.
摘要：
■抗生素耐药性的增加是导致幽门螺杆菌（H.幽门螺杆菌)根除失败。作为营养补充剂，卵黄抗体(IgY)为幽门螺杆菌感染的抢救治疗提供了新的途径。
■在这个随机的，对照研究,纳入100例先前接受幽门螺杆菌根除治疗的幽门螺杆菌阳性患者。所有个体接受标准的含铋的四联疗法，每天两次（5毫克艾普拉唑，100毫克多西环素,500毫克克拉霉素或1克阿莫西林或100毫克呋喃唑酮，和220毫克胶体酒石酸铋），持续14天，并随机接受每日两次7克IgY-H。幽门螺杆菌治疗(研究组)与否(对照组)。治疗结束后4周，尿素呼气试验用于评估幽门螺杆菌根除率.所有参与者通过全球总体症状量表（GOS）进行评分，并记录试验期间的不良事件。
■幽门螺杆菌根除率为84.0%（95%CI73.5-94.5%）在意向治疗（ITT）分析中，研究组和对照组的80.0％（95％CI68.5-91.5％）和85.7％（95％CI75.6-95.9％）与符合方案（PP）分析为80.0%（95%CI68.5-91.5%），分别。两组治疗后症状缓解超过80%的人数分别为27例(60%)和12例(29.2%)(p<0.05),不良事件发生率分别为4例（8%）和6例（12%），分别。
■两组在幽门螺杆菌抢救治疗和IgY-H方面均取得了满意的根除效果。pylori有效缓解症状，依从性好，不良反应少。
■在这个随机的，对照研究,纳入100例先前接受幽门螺杆菌根除治疗的幽门螺杆菌阳性患者。所有个体接受标准的含铋的四联疗法，每天两次（5毫克艾普拉唑，100毫克多西环素,500毫克克拉霉素或1克阿莫西林或100毫克呋喃唑酮，和220毫克胶体酒石酸铋），持续14天，并随机接受每日两次7克IgY-H。幽门螺杆菌治疗(研究组)与否(对照组)。治疗结束后4周，尿素呼气试验用于评估幽门螺杆菌根除率.所有参与者通过全球总体症状量表（GOS）进行评分，并记录试验期间的不良事件。
■幽门螺杆菌根除率为84.0%（95%CI73.5-94.5%）在意向治疗（ITT）分析中，研究组和对照组的80.0％（95％CI68.5-91.5％）和85.7％（95％CI75.6-95.9％）与符合方案（PP）分析为80.0%（95%CI68.5-91.5%），分别。两组治疗后症状缓解超过80%的人数分别为27例(60%)和12例(29.2%)(p<0.05),不良事件发生率分别为4例（8%）和6例（12%），分别。
■两组在幽门螺杆菌抢救治疗和IgY-H方面均取得了满意的根除效果。pylori有效缓解症状，依从性好，不良反应少。
